- Home
- VERU vs KLRS Comparison
VERU vs KLRS Comparison
Compare VERU & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VERU
- KLRS
- Stock Information
- Founded
- VERU 1971
- KLRS 2019
- Country
- VERU United States
- KLRS United States
- Employees
- VERU N/A
- KLRS N/A
- Industry
- VERU Biotechnology: Pharmaceutical Preparations
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VERU Health Care
- KLRS Health Care
- Exchange
- VERU Nasdaq
- KLRS Nasdaq
- Market Cap
- VERU 40.6M
- KLRS 46.0M
- IPO Year
- VERU 1990
- KLRS N/A
- Fundamental
- Price
- VERU $2.17
- KLRS $6.94
- Analyst Decision
- VERU Strong Buy
- KLRS Strong Buy
- Analyst Count
- VERU 2
- KLRS 3
- Target Price
- VERU $25.00
- KLRS $21.50
- AVG Volume (30 Days)
- VERU 191.3K
- KLRS 144.3K
- Earning Date
- VERU 12-15-2025
- KLRS 11-12-2025
- Dividend Yield
- VERU N/A
- KLRS N/A
- EPS Growth
- VERU N/A
- KLRS N/A
- EPS
- VERU N/A
- KLRS N/A
- Revenue
- VERU $16,886,419.00
- KLRS N/A
- Revenue This Year
- VERU N/A
- KLRS N/A
- Revenue Next Year
- VERU N/A
- KLRS N/A
- P/E Ratio
- VERU N/A
- KLRS N/A
- Revenue Growth
- VERU 337.24
- KLRS N/A
- 52 Week Low
- VERU $2.11
- KLRS $2.14
- 52 Week High
- VERU $14.20
- KLRS $12.90
- Technical
- Relative Strength Index (RSI)
- VERU 25.21
- KLRS 71.44
- Support Level
- VERU $2.11
- KLRS $5.23
- Resistance Level
- VERU $2.57
- KLRS $7.14
- Average True Range (ATR)
- VERU 0.20
- KLRS 0.58
- MACD
- VERU -0.03
- KLRS 0.23
- Stochastic Oscillator
- VERU 9.33
- KLRS 91.85
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.